Skip to content

High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy

High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy (DEX-NEF)

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03160729
Acronym
DEX-NEF
Enrollment
45
Registered
2017-05-19
Start date
2017-04-24
Completion date
2018-11-23
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Diseases, Postoperative Complications

Brief summary

The aim of this study is to investigate the effect of a single preoperative high-dose steroid injection on complications in the immediate postoperative phase after open kidney surgery (kidney resection, heminephrectomy, nephrectomy). Primary outcome is complications in the post anaesthesia care unit (PACU). Secondary outcomes are organospecific complications in the post anaesthesia phase, pain and nausea the first 5 days, seroma and wound infection the first 14 days and readmissions the first 30 days after surgery. The investigators hypothesize that the frequency of transfer to the PACU and organospecific complications will be lower among patients receiving high dose dexamethasone. The investigators hypothesize, that there will be no difference in wound infections, seroma or readmissions.

Detailed description

Post-surgery, patients are traditionally observed and treated in post-anesthesia care units (PACU) until they are discharged to the ward (or directly home) assessed by standardized international discharge criteria. The research project Why in PACU? (Rigshospitalet, Denmark), has since the beginning of 2016 systematically collected and analyzed procedure-related complications in the recovery phase. The complications include pain, nausea/vomiting, circulatory and respiratory problems, orthostatic intolerance and cognitive disorders. Common to all the above-mentioned post-operative problems are the possible links to the inflammatory response caused by the surgical trauma. Glucocorticoids can in this context be central for the reduction of acute postoperative organ dysfunctions, caused by the anti-inflammatory effect. In a number of different surgical procedures, single dose, pre-operative glucocorticoids have been shown to reduce post-operative nausea and vomiting (PONV), acute pain and need of opioids as well as accelerate the convalescence. Meta-analyses also showed that single-dose administration of glucocorticoids (methylprednisolone and dexamethasone) for surgical patients is safe as opposed to long-term treatment. The Why in PACU? database shows that 60 % of patients having open kidney surgery have complications in the PACU (primarily pain and hypoxia). Based on positive results in other procedure-specific studies, all donor-nephrectomy patients at Rigshospitalet, have received pre-operative high-dose steroids, in the form of 24 mg dexamethasone injection since mid-2015. This has resulted in a reduction of pain requiring treatment with 30 %. Prior to creating clinical recommendations and standards, it is required that the results be tested in a randomized, controlled, clinical trial. The study is not placebo-controlled since the positive effects of dexamethasone 8 mg on PONV have been shown in numerous trials, and is already being administered to all patients at the clinic. It would therefore not be ethically correct to withdraw from this practise

Interventions

DRUGDexamethasone

pre-operative, single-shot injection

Sponsors

Rigshospitalet, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Planned open kidney resection, heminephrectomy, nephrectomy Signed informed consent

Exclusion criteria

* chronic/ongoing use of glucocorticoids (except inhalation therapy) * ongoing use of immunosuppressive therapy * insulin dependent diabetes * pregnancy/breastfeeding * allergies toward study medication, or medication in a standard treatment * previous kidney resection on same side * thrombectomy in vena cava above diaphragma * surgery cannot be performed

Design outcomes

Primary

MeasureTime frameDescription
Post-operative complications24 hoursComplications requiring treatment in the PACU

Secondary

MeasureTime frameDescription
Length of stay, hospital1 monthTotal length of stay in hospital
Discharge score1 hourDischarge score (according to discharge criteria) in the operating theater
Complications24 hoursComplications requiring treatment in the ward
Pain postoperative4 daysSelf-reported pain (worst and average, days 0-4). Questionnaire.
Analgesics4 daysSelf-reported use of pain medication other than standard treatment (days 0-4). Questionnaire.
Length of stay, PACU24 hoursTotal length of stay in PACU
Antiemetics4 daysUse of antiemetics other than standard treatment (days 0-4. Questionnaire.
Sleep4 daysSelf-reported quality of sleep (days 0-4). Questionnaire.
Mental status4 daysSelf-reported feelings of anxiety, unrest, sadness (days 0-4). Questionnaire.
Wound complications30 daysWound complications/infections
Readmissions30 daysAny readmissions
Post operative nausea and vomiting (PONV)4 daysSelf-reported ponv (worst and average, days 0-4. Questionnaire.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026